Investing in small caps is definitely risky but can boost your gains substantially and over the past 12 months the ASX small ordinaries index has been mostly in green. As the Australian population is both ageing and growing, the demand for health care services is expected to grow strongly for the next four decades. Some of the health care stocks worth watching are:
BIOTRON LIMITED (ASX: BIT) – Biotron reported positive outcomes from the Phase 2 HIV-1 clinical trial in Sept ’18 and also completed Phase 2 HIV-1 clinical trial of BIT225. The company Secured $4.7 million underwriting agreement for 30 Nov ‘18 $0.06 option which places the company in a sound financial position as it focuses on commercial outcomes. The company also continued to fund and manage its research and development projects during the year ended 30 June 2018. Reflecting restrained profit was the earnings per share (EPS) negative of -0.004 AUD. The receipt of $1.07 million R&D Tax Incentive refund in Oct ’18 led to increase in cash position of the company. The stock is trading -4.762% lower at $0.100 as at November 12, 2018. The stock has undergone a performance change of 230.72% over the past 12 months period.
BARD1 LIFE SCIENCES LIMITED (ASX: BD1) – To raise approximately $3.3 million, an offer document will be sent offering a 1 for 5 pro rata non-renounceable entitlement issue to eligible shareholders at $0.02 per share. The company has posted a closing cash balance at $1.13m, as at the end of the first quarter September 30, 2018. Almost 74% up to $304k as reported during the previous quarter the net operating cash flow of the company reported a drop from $531k of which was contributed by research and development expenses on BARD1 pipeline of around $32k and $30k expenditure on patents and General administration expenses contributing to $242k. As at November 12, 2018, with a market capitalization of A$19.06 million the stock of BD1 traded higher at a market price of $0.024 it has witnessed a performance change of 228.57% over the past one year.
SUDA PHARMACEUTICALS LTD (ASX: SUD) – The company is a leader in oro-mucosal drug delivery and has attached a paper co-authored by Professor Steve Watson, a member of SUDA’s Scientific Board for the Anagrelide project. The Group reported revenue from continuing operations of $425,864 compared to the 2017 revenue of $444,029 in the reporting period. The net loss for the Consolidated Group was $5,459,278 compared to the 2017 loss of $1,238,309 after providing for an income tax benefit which was primarily due to the recognition of the legal settlement with the receiver of HC Berlin Pharma AG. As at November 12, 2018, with a market capitalization of A$15.49 million the stock of SUD traded higher at a market price of $0.007 which is at its 52-week low can be a value buy and it has witnessed a performance change of -60.61% over the past one year.
MEMPHASYS LIMITED (ASX: MEM) – Memphasys’ ‘Felix’ device has major advantages over current IVF sperm processing methods. Compared to 2017 deficiency of $2,356,669 the company established the financial year with an excess in working capital of $37,879. Compared to 2017 net assets deficiency of $402,240 the net assets of $3,351,580 in 2018. At end of the financial year Cash and cash equivalents was of $201,807 with no debt recognizes the company in a decent balance sheet position. The Group made a net loss for the year ended 30 June 2018 of $401,159 compared to 2017 loss of $1,999,891 which was due to the decrease in legal fees and a net abnormal gain reached at the settlement of debt. The stock had a flat change in price as at November 12, 2018, to trade at a market price of $0.037. Since last 12 months the stock has seen a performance change of 23.33%.
ANTISENSE THERAPEUTICS LIMITED (ASX: ANP) – The company reported a loss for the full-year ended 30 June 2018 of $2,331,015 as compared to 30 June 2017 loss of $2,754,799. The loss is after fully expensing all research and development costs. The revenue of the company went down to $25,553 down by 81.77%. No dividends have been paid or declared by the company since the beginning of the current reporting period. No dividends were paid for the previous reporting period. Pursuant to the capital raising, the company successfully raised the target amount of $5.0 million. The cash and cash equivalents at June 30, 2018 are of $1.89 million with no debt, represents a healthy balance sheet. As at November 12, 2018, with a market capitalization of A$16.72 million the stock of ANP traded higher at a market price of $0.043 it has witnessed a performance change of 42.86% over the past one year.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.